

Nomination Committee in Senzime ahead of the 2021 Annual General Meeting

Press release: Uppsala, 4 November 2020. In accordance with the resolution at the Annual General Meeting of Senzime AB (publ) on May 14, 2020, the three largest shareholders have on 1 September 2020 appointed a Nomination Committee for the 2021 Annual General Meeting.

The three largest shareholders in terms of voting rights (considering owner groupings) as of September 1, 2020 are Adam Dahlberg and his family, AB Segulah and Handelsbanken Fonder. They have each appointed a member, as set out below, to form the Senzime Nomination Committee together with the Chairman of the Board.

- Adam Dahlberg (Chairman)
- Lennart Kalén, AB Segulah
- Malin Björkmo, Handelsbanken Fonder
- Philip Siberg, Chairman of the Board of Senzime AB (publ)

The shareholders who have appointed members to the Nomination Committee represent approximately 30 percent of the voting rights of all shares in the company. Shareholders who wish to submit proposals to the Nomination Committee may do so by e-mail to valberedning@senzime.com.

For further information, please contact:

Philip Siberg, Chairman of the Board

Tel: +46 70 790 67 34 philip.siberg@senzime.com

Pia Renaudin, CEO

Tel: +46 70-813 34 17 e-mail: pia.renaudin@senzime.com

TO THE EDITORS

About Senzime

Senzime develops and markets systems, driven by unique algorithms and sensors, to follow patients' nervous systems and electrical impulses – before, during and after surgery. The company's solution is called TetraGraph, a medical technology system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow health care guidelines and drug recommendations, TetraGraph contributes to shorter hospitalizations and lower health care costs – in a world where everyone wakes up safely after surgery. The vision is a world without narcotics-related complications. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se, is Certified Adviser for Senzime. www.senzime.com